A possible better strategy may be first to allow full attainment of the robust cytotoxic activity of paclitaxel alone to the mitotic cancer cell population before exposing the remaining cells to CDK4/6 inhibitors when non-mitotic paclitaxel killing mechanism still can occur (Figure 3B). This evidence concerns the gene CDK4 and cancer.